Dashi Bao, MD
Internal Medicine · Flushing, NYNPI 1821353970
Payments from drug & device makers
Across 327 payments — averaging $25.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$3K
- AstraZeneca$521
- Novo Nordisk$499
- Amgen$457
- Amarin Pharma, Inc.$425
- Otsuka America Pharmaceutical, Inc.$368
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,17499%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 83 | $2,503 |
| AstraZeneca | 25 | $521 |
| Novo Nordisk | 15 | $499 |
| Amgen | 15 | $457 |
| Amarin Pharma, Inc. | 22 | $425 |
| Otsuka America Pharmaceutical, Inc. | 17 | $368 |
| Lilly USA, LLC | 12 | $342 |
| Boehringer Ingelheim | 19 | $340 |
| GSK | 16 | $337 |
| Exact Sciences | 17 | $312 |
| Johnson & Johnson | 8 | $310 |
| Axsome Therapeutics, Inc. | 3 | $248 |
| Merck | 9 | $178 |
| Biohaven Pharmaceutical Holding Company Ltd. | 8 | $151 |
| Hologic Sales And Service, LLC | 1 | $125 |
| ANI Pharmaceuticals, Inc. | 4 | $102 |
| Kowa Pharmaceuticals America, Inc. | 6 | $97 |
| AbbVie | 5 | $92 |
| Insmed, Inc. | 3 | $66 |
| IBSA Pharma Inc. | 4 | $66 |
| Pfizer | 4 | $64 |
| Agios Pharmaceuticals, Inc. | 3 | $63 |
| Phadia US Inc. | 4 | $63 |
| Electromed, Inc. | 1 | $58 |
| Calliditas Therapeutics US Inc. | 3 | $56 |
| Sanofi Pasteur Inc. | 3 | $54 |
| Esperion Therapeutics, Inc. | 3 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $45 |
| Phathom Pharmaceuticals, Inc. | 2 | $40 |
| Astellas Pharma US Inc | 2 | $39 |
| Eisai Inc. | 2 | $35 |
| Novartis | 1 | $25 |
| VBI Vaccine (delaware) Inc. | 1 | $24 |
| Boston Scientific | 1 | $23 |
| Incyte Corporation | 1 | $21 |
| Bayer | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vemlidy$375
- Auvelity$235
- XARELTO$179
- Sexually Transmitted Infectious Disease$125
- Xultophy 100/3.6$125
- RYBELSUS$125
- MOUNJARO$125
- Repatha$125
- EVENITY$105
How this compares
$8,216 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 156 | $121,248 |
| FarxigaDapagliflozin Propanediol | 121 | $108,626 |
| VemlidyTenofovir Alafenamide | 73 | $101,044 |
| Diclofenac Epolamine | 252 | $98,996 |
| SynjardyEmpagliflozin/Metformin Hcl | 104 | $85,874 |
| EliquisApixaban | 106 | $77,220 |
| XareltoRivaroxaban | 95 | $74,030 |
| RybelsusSemaglutide | 60 | $68,339 |
| VascepaIcosapent Ethyl | 157 | $65,570 |
| OzempicSemaglutide | 61 | $63,823 |
| TradjentaLinagliptin | 83 | $57,420 |
| ProliaDenosumab | 24 | $40,805 |
| JanumetSitagliptin Phos/Metformin Hcl | 54 | $38,266 |
| JanuviaSitagliptin Phosphate | 33 | $24,973 |
| JentaduetoLinagliptin/Metformin Hcl | 35 | $23,600 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy, Tradjenta, Jentadueto, Trijardy Xr | $340 | $311,504409 claims |
| Novo NordiskRybelsus, Ozempic | $499 | $132,162121 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $521 | $117,337135 claims |
| GileadVemlidy | $2,503 | $101,04473 claims |
| PfizerEliquis | $64 | $77,220106 claims |
| Johnson & JohnsonXarelto | $310 | $74,03095 claims |
| MerckJanumet, Januvia | $178 | $63,23987 claims |
| AmgenProlia | $457 | $40,80524 claims |
| GSKTrelegy Ellipta, Shingrix | $337 | $21,80964 claims |
| AbbVieLinzess | $92 | $10,25816 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Flushing
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.